Abstract
Objectives and methods:
DRF 8417, a novel oxazolidinone, has been evaluated against Gram-positive and fastidious Gram-negative bacteria. In vitro activity of DRF 8417 was determined by broth microdilution method and in vivo efficacy studies were carried out in different murine systemic infection models.
Results:
DRF 8417 exhibited potent activity against Gram-positive pathogens with MIC(50) and MIC(90) values ranging from 0.06 to 1 mg/L. MICs against Haemophilus influenzae and Moraxella catarrhalis were one to two dilutions lower than those of linezolid. The in vivo efficacy, by oral route, in different susceptible and resistant Gram-positive systemic bacterial infection models ranged from 2.0 to 2.9 mg/kg.
Conclusions:
These studies displayed the excellent in vitro and in vivo activity of DRF 8417 against Gram-positive pathogens and lower MICs when compared with linezolid against H. influenzae and M. catarrhalis.
MeSH terms
-
Animals
-
Anti-Infective Agents* / chemistry
-
Anti-Infective Agents* / pharmacology
-
Anti-Infective Agents* / therapeutic use
-
Disease Models, Animal
-
Female
-
Gram-Negative Bacterial Infections / drug therapy*
-
Gram-Negative Bacterial Infections / microbiology
-
Gram-Positive Bacterial Infections / drug therapy*
-
Gram-Positive Bacterial Infections / microbiology
-
Gram-Positive Cocci / drug effects*
-
Haemophilus Infections / drug therapy
-
Haemophilus Infections / microbiology
-
Haemophilus influenzae / drug effects*
-
Haemophilus influenzae / enzymology
-
Humans
-
Male
-
Mice
-
Microbial Sensitivity Tests
-
Moraxella catarrhalis / drug effects*
-
Moraxellaceae Infections / drug therapy
-
Moraxellaceae Infections / microbiology
-
Oxazolidinones* / chemistry
-
Oxazolidinones* / pharmacology
-
Oxazolidinones* / therapeutic use
-
Specific Pathogen-Free Organisms
-
Treatment Outcome
-
beta-Lactam Resistance
-
beta-Lactamases / metabolism
Substances
-
Anti-Infective Agents
-
Oxazolidinones
-
beta-Lactamases